This podcast was funded by GSK and is intended for healthcare professionals only. GSK has no role in the review of the content, which is independently and entirely drafted by (es.EMJ) and its collaborators.
This podcast episode focuses on two abstracts presented at EHA 2025 on momelotinib for the treatment of myelofibrosis in patients with moderate to severe anaemia, with experts Francesca Palandri and Donal McLornan.
Listen as they discuss:
- Post-hoc and subgroup analyses of the phase III SIMPLIFY-1 and MOMENTUM trials
- The importance of early therapeutic intervention in patients with anaemia
- Real-world insight into what results mean for patients and clinicians
Speakers:
Donal McLornan1
Francesca Palandri1
1. Department of Haematology and Stem Cell Transplantation | University College London Hospitals NHS Trust
2. Institute of Hematology “L. and A. Seràgnoli”, IRCCS AOU of Bologna, University of Bologna
